Search
bezafibrate (Bezalip)
Indications:
- hyperlipidemia
- primary biliary cholangitis
- add-on therapy to ursodeoxycholic acid [2]
* not shown to reduce cardiovascular events [1] (avoid)
* gemfibrozil is agent of choice in this class
Interactions
drug adverse effects of anti-hyperlipidemic agents
monitor with fibrates
General
fibrate
Database Correlations
PUBCHEM cid=39042
References
- Therapeutics Letter #108. Therapeutics Initiative
Drugs to Avoid.
http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/
- Corpechot C, Chazouilleres O, Rousseau A et al
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary
Cholangitis.
N Engl J Med 2018; 378:2171-2181. June 7, 2018
PMID: 29874528
https://www.nejm.org/doi/full/10.1056/NEJMoa1714519
- Carey EJ
Progress in Primary Biliary Cholangitis.
N Engl J Med 2018; 378:2234-2235. June 7, 2018
PMID: 29874531
https://www.nejm.org/doi/full/10.1056/NEJMe1804945